[ 2 ] Yoon DH, ChoiDR, AhnH J, et al. Ki-67 expression as a prognostic factor in diffuse large B-cell lymphoma patients treated with rituximab plus CHOP[J]. Eur J Haematol, 2010, 85(2): 149-157.
[3]
[ 3 ] Kimby E, Brandt L, Nygren P, et al. A systematic overview of chemotherapy effects in aggressive non-Hodgkin′s lymphoma[J]. Acta Oncol, 2001, 40(3): 198-212.
[4]
[ 4 ] Christopher RF, Rajni Sinha, Julie MV. Improving outcomes for patients with diffuse large B-Cell lymphoma[J]. CA Cancer J Clin, 2010, 60(10): 393-408.
[5]
[ 5 ] Moskowitz CH, Schoder H, Teruya-Feldstein J, et al. Risk-adapted dose-dense immuno- chemotherapy determined by interim FDG-PET in advanced-stage diffuse large B-cell lymphoma[J]. J Clin Oncol, 2010, 28(5):1896-1903.
[6]
[ 6 ] Savage DG, Rule SA, Tighe M, et al. Gemcitabine for relapsed or resistant lymphoma[J]. Ann Oncol, 2000, 11(5): 595-597.
[7]
[ 7 ] Zinzani PL, Magagnoli M, Bendandi M, et al. Therapy with gemcitabine in pretreated peripheral T-cell lymphoma patients[J]. Ann Oncol, 1998, 9(6): 1351-1353.
